ATLANTA — Emory University is participating in a Phase I clinical trial testing the safety and immune responses of a vaccine against the B.1.351 variant of the SARS-CoV-2 virus. The first doses were administered at the Hope Clinic of Emory Vaccine Center on Wednesday, March 31.
The vaccine was developed by Moderna, Inc. It uses the same mRNA technology as the Moderna vaccine that was authorized by the FDA in December, and is now being distributed nationwide. This new trial is being led and supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.